Inactive Instrument

Syneos Health, Inc.

Equities

SYNH

US87166B1026

Biotechnology & Medical Research

SYNEOS HEALTH, INC. : Change in Directors or Principal Officers (form 8-K)

November 16, 2021 at 05:06 pm EST

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On November 12, 2021, Thomas Allen resigned as a member of the Board of Directors of Syneos Health, Inc. (the "Company"), effective immediately. Mr. Allen's decision was not related to the Company's operations, policies, practices or financial performance.

--------------------------------------------------------------------------------

Latest news about Syneos Health, Inc.

Syneos Health Names Colin Shannon CEO	23-10-03	MT
Syneos Health, Inc. Announces Chief Executive Officer Changes	23-10-03	CI
Syneos Health, Inc.(NasdaqGS:SYNH) dropped from S&P 400	23-09-29	CI
Syneos Health, Inc.(NasdaqGS:SYNH) dropped from S&P 400 Health Care	23-09-29	CI
Syneos Health, Inc.(NasdaqGS:SYNH) dropped from S&P Composite 1500	23-09-29	CI
Syneos Health, Inc.(NasdaqGS:SYNH) dropped from S&P TMI Index	23-09-29	CI
Syneos Health, Inc.(NasdaqGS:SYNH) dropped from S&P 1000	23-09-29	CI
Syneos Health, Inc.(NasdaqGS:SYNH) dropped from S&P Global BMI Index	23-09-29	CI
Syneos Health, Inc. Announces Management Changes	23-09-28	CI
Syneos Health, Inc.(NasdaqGS:SYNH) dropped from NASDAQ Composite Index	23-09-28	CI
Syneos Health, Inc.'s Equity Buyback announced on June 1, 2022, has expired.	23-09-27	CI
Patient Square Capital, LP, Elliott Investment Management L.P. and Veritas Capital Fund Management, L.L.C completed the acquisition of Syneos Health, Inc. from a group of shareholders.	23-09-27	CI
Civitas Resources to be Added to S&P MidCap 400; Hayward Holdings to Join S&P SmallCap 600	23-09-27	MT
Syneos Health, Inc.(NasdaqGS:SYNH) dropped from NASDAQ Biotechnology Index	23-09-27	CI
Syneos Health Names Terttu Haring President, Clinical Sites & Patients	23-09-26	CI
Syneos Health, Oracle Collaborate to Speed Up Patient Recruitment for Clinical Studies	23-09-12	MT
Large LBO bond sales could prompt September US junk debt rush	23-09-07	RE
Syneos Health, Star Parent Plan $1.70 Billion Senior Secured Notes Offering	23-09-06	MT
European Commission Clears Joint Acquisition of Syneos Health	23-08-16	MT
Tranche Update on Syneos Health, Inc.'s Equity Buyback Plan announced on June 1, 2022.	23-08-09	CI
Syneos Health, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-09	CI
Syneos Health Gets Shareholder Approval for Acquisition Deal	23-08-02	MT
Click Therapeutics Launches Additional Randomized Clinical Study in Migraine, Conducted in Partnership with Syneos Health	23-08-02	CI
Syneos Health Appoints Hillary Bochniak as Chief Human Resources Officer	23-07-10	CI
Syneos Health, uMotif to Collaborate on Digital Platform for Clinical Trials	23-06-26	MT

Chart Syneos Health, Inc.

Duration

Period

More charts

Company Profile

Syneos Health, Inc. is a biopharmaceutical solutions company that utilizes outsourced clinical drug development and commercialization services. The Company operates through two business segments: Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers global services for the development of diagnostics, drugs, biologics, devices, and digital therapeutics that span Phase I to IV of clinical development. The Clinical Solutions segment offers individual services including product development, project management, protocol development, investigational site recruitment, and clinical monitoring. The Commercial Solutions segment provides commercialization services, including deployment solutions, communications solutions (public relations, advertising, and medical communications), and consulting services. The Company's customers include small, mid-sized, and large companies in the biopharmaceutical, biotechnology, and medical device industries.

Sector

Biotechnology & Medical Research

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
IQVIA HOLDINGS INC.	+1.12%	42.59B
MODERNA, INC.	+6.77%	40.65B
LONZA GROUP AG	+47.41%	40.57B
CELLTRION, INC.	-11.96%	26.77B
ICON PUBLIC LIMITED COMPANY	+6.01%	24.81B
ALNYLAM PHARMACEUTICALS, INC.	-24.92%	18.17B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.63%	11.7B
MEDPACE HOLDINGS, INC.	+27.16%	12.05B
UNITED THERAPEUTICS CORPORATION	+7.30%	11.1B

Other Biotechnology & Medical Research